Labcorp (LH - Free Report) reported $3.06 billion in revenue for the quarter ended September 2023, representing a year-over-year decline of 15.2%. EPS of $3.38 for the same period compares to $4.68 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $2.99 billion, representing a surprise of +2.14%. The company delivered an EPS surprise of +0.30%, with the consensus EPS estimate being $3.37.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Labcorp performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Biopharma Laboratory Services: $719.10 million compared to the $729.12 million average estimate based on three analysts. The reported number represents a change of -48.9% year over year.
- Revenues- Diagnostics Laboratories: $2.34 billion versus $2.26 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +6.2% change.
- Adjusted Operating Income- Diagnostics Laboratories: $386.30 million versus the three-analyst average estimate of $378.31 million.
- Adjusted Operating Income- Unallocated corporate expense: -$71.40 million versus -$48.33 million estimated by three analysts on average.
- Adjusted Operating Income- Biopharma Laboratory Services: $109 million compared to the $108.88 million average estimate based on three analysts.
View all Key Company Metrics for Labcorp here>>>Shares of Labcorp have returned -3.5% over the past month versus the Zacks S&P 500 composite's -3.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How To Profit From Trillions On Spending For Infrastructure >>
Labcorp (LH - Free Report) reported $3.06 billion in revenue for the quarter ended September 2023, representing a year-over-year decline of 15.2%. EPS of $3.38 for the same period compares to $4.68 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $2.99 billion, representing a surprise of +2.14%. The company delivered an EPS surprise of +0.30%, with the consensus EPS estimate being $3.37.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Labcorp performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Biopharma Laboratory Services: $719.10 million compared to the $729.12 million average estimate based on three analysts. The reported number represents a change of -48.9% year over year.
- Revenues- Diagnostics Laboratories: $2.34 billion versus $2.26 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +6.2% change.
- Adjusted Operating Income- Diagnostics Laboratories: $386.30 million versus the three-analyst average estimate of $378.31 million.
- Adjusted Operating Income- Unallocated corporate expense: -$71.40 million versus -$48.33 million estimated by three analysts on average.
- Adjusted Operating Income- Biopharma Laboratory Services: $109 million compared to the $108.88 million average estimate based on three analysts.
View all Key Company Metrics for Labcorp here>>>Shares of Labcorp have returned -3.5% over the past month versus the Zacks S&P 500 composite's -3.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How To Profit From Trillions On Spending For Infrastructure >>
Get the latest research report on LH - FREE